Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF). We report phase 1 studies investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG1690 in healthy subjects. We performed a first‐in‐human randomize...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: van der Aar, Ellen, Desrivot, Julie, Dupont, Sonia, Heckmann, Bertrand, Fieuw, Ann, Stutvoet, Simone, Fagard, Liesbeth, Van de Wal, Karen, Helmer, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Pharmacokinetics/Pharmacodynamics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767429/
https://ncbi.nlm.nih.gov/pubmed/31012984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1424
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados